15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Autolus Therapeutics Ltd, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 585% above the current $1.46. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 72% this year and 48% next, consensus EPS building from about $-0.21 next quarter toward $-0.61 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Autolus Therapeutics Ltd.
As of Jul, 4 of 4 firms rate AUTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AUTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.27 – $-0.17 · 6 analysts · -31% YoY
Next period, 6 analysts expect Autolus Therapeutics Ltd to earn $-0.21 a share (range $-0.27 – $-0.17), versus $-0.30 a year earlier. Full-year consensus is $-0.89, growing to $-0.61 the year after.
REVENUE · NEXT QUARTER
$33.1M
Range $31.7M – $34.8M · 6 analysts · +45% YoY
Revenue is expected to reach $33.1M (range $31.7M – $34.8M), +45.0% year-over-year. Full-year consensus is $128.6M, rising to $191.0M next year.
Top analysts covering Autolus Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUTL.
#1
Gil Blum
Needham · Rank #298
Buy
$10.00+584.9% to target
Overall win rate
24%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$10.00+584.9% to target
Overall win rate
22%
+ Follow
#3
Salim Syed
Mizuho
Buy
$10.00+584.9% to target
Coverage
—
+ Follow
#4
Asthika Goonewardene
Truist Securities
Buy
$8.00+447.9% to target
Coverage
—
+ Follow
AUTL stock forecast FAQ
What is AUTL's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Autolus Therapeutics Ltd over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is AUTL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover AUTL?+
4 analysts have an active rating on Autolus Therapeutics Ltd, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering AUTL?+
Among analysts who currently cover AUTL, Gil Blum of Needham has the strongest overall Quantellect track record (Rank #298). Their current call is Buy with a $10.00 target.
What is Autolus Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.27 – $-0.17) across 6 analysts. Full-year EPS is projected at $-0.89, rising to $-0.61 the following year.
How much revenue is Autolus Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $33.1M (range $31.7M – $34.8M). Full-year revenue is projected at $128.6M, growing to $191.0M next year.
Have analysts been upgrading or downgrading AUTL lately?+
As of Jul, 4 of 4 firms rate AUTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
